RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00127582|
Recruitment Status : Unknown
Verified May 2005 by Catholic University of the Sacred Heart.
Recruitment status was: Recruiting
First Posted : August 8, 2005
Last Update Posted : August 25, 2005
|Condition or disease||Intervention/treatment||Phase|
|Myotonic Dystrophy Sudden Cardiac Death||Procedure: Electrophysiological study Device: pacemaker (PM) implant, internal cardiac defibrillator (ICD) implant, loop-recorder implant||Phase 3|
Myotonic dystrophy type 1 (DM1, Steinert disease) is a multisystem disorder that affects, beside muscle, several other organs, including the heart.
Cardiac involvement represents a major problem in the clinical management of patients, so that cardiac complications represent one of the primary causes of premature death in DM1. In particular there is a high incidence of sudden death, ranging from 2 to 30% of cases, so far principally related to the development of conduction blocks. However, literature reports of sudden death in patients implanted with pacemakers, as well as of spontaneous ventricular tachycardia would suggest a potential etiologic role also for ventricular arrhythmias. The lack of clinical research studies conducted on a large number of patients does not make available definite data regarding the etiology and the epidemiology of arrhythmic events in DM1. For the same reasons, other considerable topics, such as prognostic stratification of the arrhythmic risk and clinical management of life-threatening arrhythmias in DM1 patients, are still undefined.
To clarify these issues, the investigators propose a clinical research study performed on a large cohort of DM1 patients enrolled through a multicenter collaboration that also involves 5 cardiological-neurological Italian centres.
Aims of this study are:
- To estimate the incidence of arrhythmias and to characterize the brady-tachyarrhythmic mechanisms underlying the occurrence of cardiac sudden death in DM1;
- To verify by statistical analysis the reliability of data obtained from both non invasive and invasive diagnostic procedures as indexes useful for estimating the arrhythmic risk in DM1;
- To identify more adequate therapeutic guidelines in order to prevent the occurrence of life-threatening arrhythmias.
The protocol of study includes:
- Clinical-genetic evaluation;
- Non invasive and invasive diagnostic cardiac procedures;
- The use of devices for diagnostic and therapeutic follow-up.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||537 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of Arrhythmic Risk in Myotonic Dystrophy Type I (DM 1)|
|Study Start Date :||January 2003|
- Evaluate incidence of: major cardiac events (sudden death
- resuscitated cardiac arrest
- ventricular fibrillation
- sustained ventricular tachycardia
- sinoatrial and atrioventricular [AV] blocks)
- Evaluate with diagnostic non-invasive (standard electrocardiogram [ECG]
- 24-hour monitoring ECG
- signal-averaged ECG
- echocardiography) and invasive procedures (electrophysiology study [EPS] and implantable loop recorders) the risk to develop cardiac arrhythmias in DM patients
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00127582
|Contact: Fulvio Bellocci, MDfirstname.lastname@example.org|
|Contact: Antonio Dello Russo, MDemail@example.com|
|Catholic University of Sacred Heart||Recruiting|
|Rome, Italy, 00168|
|Contact: Fulvio Bellocci, MD +390630154187 firstname.lastname@example.org|
|Principal Investigator: Fulvio Bellocci, MD|
|Principal Investigator:||Fulvio Bellocci, MD||Catholic University of Sacred Heart|